Abstract 486P
Background
Somatic inactivation of the NF1 gene is frequent in breast cancer, particularly in advanced stages, and it has been suggested as a potential mechanism of resistance to endocrine therapy. Pathogenic germline variants of the NF1 gene cause neurofibromatosis 1 (NF1) syndrome that is associated with an increased risk for breast cancer and reduced estrogen receptor expression in breast cancer. The present study aims to explore the consequences of somatic and germline NF1 mutations in hormone receptor positive and negative breast cancer.
Methods
In order to study germline NF1 alterations, a Finnish cohort of 1,811 individuals with verified NF1 syndrome (926 women) and a ten-fold control cohort were cross-referenced with the Finnish Cancer Registry. The process identified 49 women with NF1 and 226 controls who had been diagnosed with breast cancer between 1996 and 2020. The analysis was limited to non-localized disease. Register-based information on endocrine therapy was used as a proxy for hormone receptor status. Survival after breast cancer with or without somatic NF1 deficiency was analyzed using the METABRIC dataset, which contained 582 breast cancers harboring somatic alterations of the NF1 gene, and 1,392 tumors where the NF1 gene was intact. Cox proportional hazards models were used to estimate hazard ratios (HRs) and their 95% confidence intervals (CI).
Results
Somatic NF1 alterations were associated with worse prognosis compared to tumors with normal NF1 after estrogen receptor positive breast cancer (HR 1.53, 95% CI 1.16-2.02) while the NF1 alteration status had no effect on survival after the diagnosis of an estrogen receptor negative breast cancer (HR 1.10, 95% CI 0.80-1.52). In contrast, pathogenic germline variants of the NF1 gene were not associated with decreased survival in patients with or without endocrine therapy (HR 0.76, 95% CI 0.28-2.04; and HR 1.04, 95% CI 0.40-2.70, respectively).
Conclusions
Only somatic alterations of the NF1 gene modify endocrine therapy outcomes in breast cancer. This suggests that estrogen receptor-positive breast cancer employs a different pathway for estrogen receptor signaling in women with pathogenic germline NF1 variants than in the setting of somatic NF1 inactivation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cancer Foundation Finland, Turku University Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
489P - Liquid biopsy with combination of cell & cell-free analysis identifies HER2-expression in patients with metastatic breast cancer
Presenter: Fengting Yan
Session: Poster session 04
491P - Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
Presenter: Nina Dobrić
Session: Poster session 04
492P - Wound stress stimulation promotes lung metastasis of breast cancer by regulating CXCL12/CXCR4 axis through MDSC exosome miR-126a-5p
Presenter: Xiaomeng Yin
Session: Poster session 04
493P - Identifying genomic changes in breast tumours that metastasise to the brain
Presenter: Ivonne Olivares
Session: Poster session 04
494P - Proviral insertion in murine 1 (PIM1) kinase expression and clinical outcomes in advanced breast cancer (ABC)
Presenter: Stephanie Graff
Session: Poster session 04
495P - Prognostic value of PIK3CA mutational status in tissue & plasma in HR+/HER2- breast cancer (BC)
Presenter: Rebeca Lozano Mejorada
Session: Poster session 04
496P - Comprehensive genomic profiling of advanced HR+/HER2- breast cancer patients using liquid biopsy
Presenter: Bin Shao
Session: Poster session 04
497P - Metastatic potential of the somatic alteration associated with TCA-cycle in breast cancer
Presenter: Narumi Harada
Session: Poster session 04
1265P - Toripalimab plus chemotherapy as neoadjuvant treatment for resectable stage IIB-IIIB NSCLC (RENAISSANCE study): A single-arm, phase II trial
Presenter: Shi Yan
Session: Poster session 04